Study of Depemokimab to Improve Lung Structure and Function in Adults with Type 2 Inflammatory Asthma Using Imaging and Bronchoscopy

What this Trial Is About

Asthma is a long-term condition where the airways become narrow and swollen due to inflammation, causing symptoms that can vary and worsen unexpectedly. This trial is evaluating depemokimab, a monoclonal antibody, to see how it impacts lung structure and function in adults with type 2 inflammatory asthma, particularly those with an eosinophilic phenotype. The study is a Phase 3b treatment trial sponsored by GlaxoSmithKline. Participants with asthma characterized by type 2 inflammation will receive depemokimab. The study uses advanced imaging and bronchoscopy to assess changes in lung features. Treatment involves administering depemokimab, with evaluations performed up to 52 weeks. Participants who consent to a biopsy sub-study will undergo additional bronchoscopy procedures under specific safety criteria. During the study, participants will undergo lung imaging, bronchoscopy, and tests measuring mucus plug volume, airway wall thickness, and lung function at several time points including weeks 26 and 52. Researchers will monitor side effects and serious adverse events up to 65 weeks. The total study duration allows detailed assessment of depemokimabs effects on lung health and participant safety.

Depemokimab Asthma Imaging and Bronchoscopy Sub-Study